Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 26.7 | uM | 12523.168 | 0.6637 | 0.2707 | 0.9035 | |
| HCC1569 | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 12523.168 | 0.0340 | -0.9526 | 0.9035 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 12239.144 | 0.9925 | 0.9930 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 12239.144 | 1.0536 | 1.0490 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 12239.144 | 0.9832 | 0.9844 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 12239.144 | 0.9070 | 0.9116 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.213 | uM | 12239.144 | 0.8241 | 0.8286 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 1.07 | uM | 12239.144 | 0.8223 | 0.8268 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 5.33 | uM | 12239.144 | 0.8001 | 0.8038 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 26.7 | uM | 12239.144 | 0.6005 | 0.5793 | 2.1598 | |
| HCC1806 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 12239.144 | 0.0207 | -0.6680 | 2.1598 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 11849.144 | 0.9594 | 0.9421 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 11849.144 | 0.9107 | 0.8719 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 11849.144 | 0.8039 | 0.7137 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 11849.144 | 0.7021 | 0.5572 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.213 | uM | 11849.144 | 0.6628 | 0.4950 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 1.07 | uM | 11849.144 | 0.6712 | 0.5083 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 5.33 | uM | 11849.144 | 0.6507 | 0.4756 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 26.7 | uM | 11849.144 | 0.5119 | 0.2452 | 1.4131 | |
| HCC1937 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 11849.144 | 0.1720 | -0.4246 | 1.4131 | |
| HCC1954 | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 11055.144 | 0.9303 | 0.9154 | 1.6716 | |
| HCC1954 | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 11055.144 | 0.9035 | 0.8822 | 1.6716 | |
| HCC1954 | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 11055.144 | 0.7514 | 0.6857 | 1.6716 | |
| HCC1954 | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 11055.144 | 0.6386 | 0.5294 | 1.6716 | |
| HCC1954 | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.213 | uM | 11055.144 | 0.6109 | 0.4893 | 1.6716 |